Back to CITADEL ADVISORS LLC CITADEL ADVISORS LLC

DYNDYN
Showing 8 of 24 quarters

Position history for CITADEL ADVISORS LLCCITADEL ADVISORS LLC's holdings in DYNE THERAPEUTICS INC

Yes. Citadel Advisors holds 1,143,958 shares of DYN (Dyne Therapeutics), worth $25.4M, as of its Q2 2026 13F filing. It increased the position from 201,144 shares in Q1 2026. Citadel Advisors has held DYN in every 13F on record since Q3 2020, 24 quarterly filings.

Current Value

$25.4M

Current Shares

1.1M

Total Value Change

-$80.2M

Total Shares Change

-1.8M

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Increased
1.1M
+468.7%
$25.4M0.0%$22.21
46
2026-Q1
Decreased
201,144
-82.8%
$3.6M0.0%$14.60
0
2025-Q4
Decreased
1.2M
-65.7%
$22.9M0.0%$19.20
0
2025-Q3
Increased
3.4M
+261.6%
$43.2M0.0%$12.37
47
2025-Q2
Decreased
943,874
-68.6%
$9M0.0%$9.57
0
2025-Q1
Increased
3M
+5.2%
$31.5M0.0%$11.45
30
2024-Q4
Decreased
2.9M
-2.6%
$67.4M0.0%$23.65
0
2024-Q3
Decreased
2.9M
-31.9%
$105.6M0.0%$33.83
0

Other major holders of DYN: FMR LLC, BlackRock, Inc., Janus Henderson Group Ltd., Jupiter Topco LLC

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used